Table III.
Previous studies on chemotherapy for locally advanced unresectable pancreatic cancer.
| No. | First author | Year | Patient no. | Regimen | RR (%) | CS (%)/R0 resection (%) | MST (months) | (Refs.) |
|---|---|---|---|---|---|---|---|---|
| 1 | Habermehl | 2012 | 198 | GEM/radiation | 9 | 26/39 | 12.3 | (15) |
| 2 | Faris | 2013 | 22 | FOLFIRINOX | 27.3 | 22/60 | NA | (3) |
| 3 | Nanda | 2015 | 15 | FOLFIRINOX | NA | 13/NA | 18.6 | (16) |
| 4 | Blazer | 2015 | 25 | FOLFIRINOX | 9 | 44/91 | 21.2 | (17) |
| 5 | Present study | 2015 | 7 | GEM/nab-PTX | 71 | 29/100 | (mean) 13.3 |
GEM, gemcitabine; FOLFIRINOX, 5- fluorouracil/leucovorin plus oxaliplatin and irinotecan; nab-PTX, nab-paclitaxel; RR, response rate; CS, conversion surgery; MST, median survival time; NA, not applicable.